Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3913 | LAMB2 | LN46 | Human | Oral cavity | OSCC | 9.26e-03 | 1.54e-01 | 0.1666 |
3913 | LAMB2 | LP15 | Human | Oral cavity | LP | 1.05e-02 | 6.90e-01 | 0.2174 |
3913 | LAMB2 | NEOLP-2 | Human | Oral cavity | NEOLP | 1.70e-02 | 1.23e-01 | -0.0196 |
3913 | LAMB2 | NEOLP-3 | Human | Oral cavity | NEOLP | 2.16e-03 | 7.40e-02 | -0.0191 |
3913 | LAMB2 | SYSMH3 | Human | Oral cavity | OSCC | 3.99e-10 | 2.94e-01 | 0.2442 |
3913 | LAMB2 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 8.35e-03 | 3.10e-01 | -0.2247 |
3913 | LAMB2 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 6.87e-03 | 2.86e-01 | -0.1833 |
3913 | LAMB2 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 1.73e-03 | 2.80e-01 | -0.23 |
3913 | LAMB2 | 048752_1579-all-cells | Human | Prostate | BPH | 4.81e-04 | 2.27e-01 | 0.1008 |
3913 | LAMB2 | Dong_P1 | Human | Prostate | Tumor | 2.08e-14 | 9.44e-02 | 0.035 |
3913 | LAMB2 | Dong_P3 | Human | Prostate | Tumor | 2.07e-16 | 2.37e-01 | 0.0278 |
3913 | LAMB2 | Dong_P5 | Human | Prostate | Tumor | 1.39e-08 | 4.60e-02 | 0.053 |
3913 | LAMB2 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 1.34e-11 | 7.27e-01 | 0.1633 |
3913 | LAMB2 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 6.18e-12 | 6.62e-01 | 0.1608 |
3913 | LAMB2 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 2.48e-16 | 8.96e-01 | 0.1604 |
3913 | LAMB2 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 8.01e-10 | 6.56e-01 | 0.1621 |
3913 | LAMB2 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.51e-04 | 6.53e-01 | 0.1619 |
3913 | LAMB2 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 2.44e-07 | 6.07e-01 | 0.1602 |
3913 | LAMB2 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 3.69e-08 | 8.29e-01 | 0.1608 |
3913 | LAMB2 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 1.44e-06 | 8.45e-01 | 0.1622 |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LAMB2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LAMB2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/LAMB2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/LAMB2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003158912 | Liver | Cirrhotic | cell-substrate adhesion | 128/4634 | 363/18723 | 4.10e-06 | 6.90e-05 | 128 |
GO:003444612 | Liver | Cirrhotic | substrate adhesion-dependent cell spreading | 47/4634 | 108/18723 | 1.48e-05 | 2.05e-04 | 47 |
GO:001604911 | Liver | Cirrhotic | cell growth | 160/4634 | 482/18723 | 1.50e-05 | 2.07e-04 | 160 |
GO:000206412 | Liver | Cirrhotic | epithelial cell development | 80/4634 | 220/18723 | 7.63e-05 | 8.44e-04 | 80 |
GO:003109911 | Liver | Cirrhotic | regeneration | 71/4634 | 198/18723 | 3.02e-04 | 2.65e-03 | 71 |
GO:0071711 | Liver | Cirrhotic | basement membrane organization | 17/4634 | 31/18723 | 3.19e-04 | 2.77e-03 | 17 |
GO:0042063 | Liver | Cirrhotic | gliogenesis | 98/4634 | 301/18723 | 1.28e-03 | 8.60e-03 | 98 |
GO:0010001 | Liver | Cirrhotic | glial cell differentiation | 75/4634 | 225/18723 | 2.24e-03 | 1.36e-02 | 75 |
GO:0072015 | Liver | Cirrhotic | glomerular visceral epithelial cell development | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0072310 | Liver | Cirrhotic | glomerular epithelial cell development | 8/4634 | 13/18723 | 5.27e-03 | 2.70e-02 | 8 |
GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
GO:003444622 | Liver | HCC | substrate adhesion-dependent cell spreading | 67/7958 | 108/18723 | 3.24e-05 | 3.28e-04 | 67 |
GO:003158922 | Liver | HCC | cell-substrate adhesion | 188/7958 | 363/18723 | 2.00e-04 | 1.55e-03 | 188 |
GO:00310992 | Liver | HCC | regeneration | 107/7958 | 198/18723 | 6.67e-04 | 4.12e-03 | 107 |
GO:006056011 | Liver | HCC | developmental growth involved in morphogenesis | 124/7958 | 234/18723 | 7.37e-04 | 4.47e-03 | 124 |
GO:00016553 | Liver | HCC | urogenital system development | 170/7958 | 338/18723 | 2.15e-03 | 1.08e-02 | 170 |
GO:004867511 | Liver | HCC | axon extension | 67/7958 | 120/18723 | 2.17e-03 | 1.09e-02 | 67 |
GO:199013811 | Liver | HCC | neuron projection extension | 92/7958 | 172/18723 | 2.31e-03 | 1.14e-02 | 92 |
GO:00723101 | Liver | HCC | glomerular epithelial cell development | 11/7958 | 13/18723 | 2.38e-03 | 1.16e-02 | 11 |
GO:004858811 | Liver | HCC | developmental cell growth | 121/7958 | 234/18723 | 2.68e-03 | 1.28e-02 | 121 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LAMB2 | SNV | Missense_Mutation | | c.5393N>T | p.Gln1798Leu | p.Q1798L | P55268 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
LAMB2 | SNV | Missense_Mutation | rs762984990 | c.3442N>T | p.Arg1148Cys | p.R1148C | P55268 | protein_coding | deleterious(0.01) | possibly_damaging(0.524) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
LAMB2 | SNV | Missense_Mutation | | c.1000C>T | p.Arg334Cys | p.R334C | P55268 | protein_coding | deleterious(0) | possibly_damaging(0.837) | TCGA-D8-A1X5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
LAMB2 | SNV | Missense_Mutation | | c.931N>G | p.Ile311Val | p.I311V | P55268 | protein_coding | tolerated(1) | benign(0) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
LAMB2 | SNV | Missense_Mutation | rs777003946 | c.1264N>T | p.Arg422Cys | p.R422C | P55268 | protein_coding | deleterious(0.03) | possibly_damaging(0.576) | TCGA-E2-A14Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
LAMB2 | SNV | Missense_Mutation | | c.4868N>A | p.Gly1623Asp | p.G1623D | P55268 | protein_coding | tolerated(0.44) | possibly_damaging(0.738) | TCGA-E2-A14Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
LAMB2 | SNV | Missense_Mutation | | c.2260N>A | p.Leu754Met | p.L754M | P55268 | protein_coding | tolerated(0.46) | benign(0.09) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
LAMB2 | SNV | Missense_Mutation | | c.3107N>G | p.His1036Arg | p.H1036R | P55268 | protein_coding | tolerated(1) | benign(0) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
LAMB2 | SNV | Missense_Mutation | | c.311N>G | p.His104Arg | p.H104R | P55268 | protein_coding | tolerated(0.37) | benign(0.02) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
LAMB2 | insertion | Nonsense_Mutation | novel | c.5165_5166insGTAGTATGTTTGAATCTTCTGATATCTCCT | p.Gln1722_Gly1723insTer | p.Q1722_G1723ins* | P55268 | protein_coding | | | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |